Exchange: NASDAQ·Updated 07:30 PM EST
FENC logo

FENC Fennec Pharmaceuticals Inc

$12.70
$1.14
(9.81%)
Today
Closed $12.76
$0.06
(0.47%)
After Hours
Reported EarningsNov 12
Mkt Cap$410.25M
Vol793,197.00

About FENC

Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.
70

Bullish Sentiment

How do you feel about FENC?

BioGem
$FENC Holding my long since last year. This company is a beast. -Excellent beat on top and bottom lines. -High margins with solid profits and positive cash flows. -No competitor in their niche = mini-monopoly. -High-quality management leading a high productivity sales team. -Market is still under-penetrated = growth rates to stay high for a while. -Ex-US milestones and royalties haven't even started contributing yet. -Low short interest. -Analyst will be rising price targets further. $XBI $XLV
2
BiotechSwings
sales doing the talking on $FENC imo PEDMARK did 19.4 million in Q3, up 56% vs last year nine months at 51.7 million vs 30.9 million trading 11.31, up 6.3% off a 10.64 close, high at 11.45 real revenue in a sector full of readout lotteries ngl
2
StocktwitsEarnings
$FENC Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $0.12 up 700.00% YoY • Reported revenue of $19.61M up 57.38% YoY
1
kwagz
$FENC Great earnings progression with positive catalysts coming. This is just the beginning. Will be adding to my core position over the next year.

Advertisement|Remove ads.